{
    "nct_id": "NCT04629729",
    "official_title": "A Phase I Study of FT819 in Subjects With B-cell Malignancies",
    "inclusion_criteria": "Diagnosis of B-cell lymphoma, CLL or B-ALL as described below:\n\nB-Cell Lymphoma:\n\n* Histologically documented lymphomas expected to express CD19\n* Relapsed/refractory disease following at least 2 prior lines of multi-agent immunochemotherapy\n\nChronic Lymphocytic Leukemia (CLL):\n\n* Diagnosis of CLL per iwCLL guidelines\n* Relapsed/refractory disease following at least two prior systemic treatment regimens\n\nPrecursor B-cell Acute Lymphocytic Leukemia (B-ALL):\n\n* Diagnosis of B-ALL by flow cytometry, bone marrow histology, and/or cytogenetics\n* Relapsed/refractory disease after at least 2 cycles of standard multiagent induction chemotherapy. For subjects with Philadelphia-chromosome positive (Ph+) disease, failure or intolerance to a tyrosine kinase inhibitor therapy-containing regimen\n\nALL SUBJECTS:\n\n* Capable of giving signed informed consent\n* Age ≥ 18 years old\n* Stated willingness to comply with study procedures and duration\n* Contraceptive use for women and men as defined in the protocol\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "ALL SUBJECTS:\n\n* Females who are pregnant or breastfeeding\n* Eastern Cooperative Oncology Group (ECOG) Performance Status ≥2\n* Body weight <50 kg\n* Evidence of insufficient organ function\n* Receipt of therapy within 2 weeks prior to Day 1 or five half-lives, whichever is shorter; or any investigational therapy within 28 days prior to Day 1\n* Currently receiving or likely to require systemic immunosuppressive therapy\n* Ongoing requirement for systemic GvHD therapy following prior allogeneic hematopoietic stem cell transplant (HSCT) or allogeneic CAR-T\n* Receipt of an allograft organ transplant\n* Known active central nervous system (CNS) involvement by malignancy\n* Non-malignant CNS disease such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease\n* Clinically significant cardiovascular disease\n* Positive serologic test results for HIV infection\n* Positive serologic and polymerase chain reaction (PCR) test results for Hepatitis B (HBV) infection\n* Positive serologic and PCR test results for Hepatitis C (HCV) infection\n* Live vaccine <6 weeks prior to start of lympho-conditioning\n* Known allergy to albumin (human) or DMSO",
    "miscellaneous_criteria": "Key"
}